Wednesday, November 11, 2026
Investing and Wealth Management

Healthcare Stocks Surge on Biotech Innovation, M&A Wave, and Strong Earnings Outlook

Raul Delapena Setiawan
Font Size:
FB X WA TG

Healthcare stocks are experiencing a powerful market resurgence, vastly outperforming broader indexes after enduring years of depressed valuations and macroeconomic headwinds. Over the past 12 months, the healthcare sector has posted impressive gains of 23%, handily outpacing the 15.7% return recorded by the S&P 500 Index.

This robust recovery marks a definitive turning point for an industry that spent years locked in a prolonged slump. According to Finny Kuruvilla, co-chief investment officer at Eventide Asset Management, the sector’s difficulties began when the biotech bubble following the launch of COVID-19 vaccines burst in 2021, setting off a grueling four-year "biotech winter."

The situation was further exacerbated by an epic rise in interest rates in 2022, which severely impacted biotech firms that rely heavily on borrowing. From its peak in early 2021 to its cyclical low in 2025, the S&P Biotechnology Select Industry Index suffered a cumulative 63% decline. Simultaneously, pharmaceutical shares faced persistent uncertainty surrounding drug pricing regulations, while post-pandemic supply gluts hindered healthcare product manufacturers and unexpected spikes in the demand for medical care squeezed insurers. Consequently, between early 2022 and mid-2025, the S&P 1500 Health Care Index delivered a paltry cumulative return of just 1.0%, while the broader U.S. stock market surged 43%.

However, the industry has firmly moved past those multi-year hurdles. Today, a convergence of groundbreaking scientific innovation, an aggressive wave of mergers and acquisitions, and a significantly improved outlook for sector earnings growth are propelling healthcare shares upward. While the healthcare sector is broad and multifaceted, certain industries stand out as primary beneficiaries of these positive trends—specifically biotechnology, select pharmaceuticals, and life science tools companies that supply the specialized instruments needed to research and develop novel therapeutics. As Sal Rais, manager of the T. Rowe Price Health Care exchange-traded fund, notes, the biotech industry is currently operating from a position of profound strength.

Healthcare Stocks Are on the Mend. Here Are 6 Ways Investors Can Cash In

Growth drivers for healthcare stocks

Over the years, steady advancements in genetics and molecular science have yielded a sophisticated array of new techniques to combat complex diseases, with biotechnology serving as the primary engine for these discoveries. The scientific toolbox available to drug developers has expanded dramatically, enabling researchers to engineer targeted therapies that are safer, more effective, and developed faster than at any point in medical history.

The industry has been particularly electrified by stunning clinical and regulatory developments surrounding advanced therapeutics. A recently approved pancreatic cancer pill, known as Rasonque and developed by Revolution Medicines, has demonstrated the ability to more than double overall survival periods to 13.2 months compared to standard chemotherapy regimens. This therapy targets specific proteins that fuel tumor growth, effectively shutting them down to halt disease progression.

In the realm of oncology, recent clinical data released by Moderna and Merck regarding a novel skin cancer protocol has likewise energized the biotech community. The Moderna vaccine is custom-designed using individual patient tumor tissue, training the human immune system to recognize and destroy malignant cells when administered alongside Merck’s Keytruda immunotherapy. Early clinical trials revealed that patients receiving this dual-treatment approach experienced a 49% lower chance of disease recurrence or death compared to those treated with Keytruda alone.

Beyond pure scientific breakthroughs, a rapid acceleration in mergers and acquisitions has provided a vital floor for valuations across the sector. Sal Rais points out that major pharmaceutical companies are facing what is anticipated to be their largest patent cliff in history, spanning from 2028 through 2032. When a major pharmaceutical firm loses its exclusive intellectual property rights to manufacture a blockbuster drug, revenues typically plummet as generic competitors enter the market. Consequently, large drugmakers face unprecedented urgency to replenish their research pipelines, driving them to aggressively acquire promising biotech companies.

Healthcare Stocks Are on the Mend. Here Are 6 Ways Investors Can Cash In

M&A activity has accelerated dramatically, with pharmaceutical companies executing 26 major acquisitions in 2025 alone, while the count surpassed 50 deals by midyear 2026. Pharmaceutical giant Eli Lilly has been particularly active, completing more business acquisitions in the first half of 2026 than it did throughout the entirety of the previous year. While Lilly chief executive David Ricks acknowledged in a financial network interview that not every corporate acquisition will ultimately succeed, the bets that do pay off are expected to fuel the company’s growth well into the 2030s.

Additionally, China has rapidly emerged as a formidable powerhouse in global drug development, creating an international pipeline of partnership opportunities. Armed with robust clinical trial data, Chinese biotech firms are increasingly collaborating with U.S. and European companies. For instance, U.S.-based Kailera Therapeutics licensed the rights outside of Greater China to develop and market a promising weight-loss drug from Jiangsu Hengrui Pharmaceuticals, leveraging that foreign asset to successfully raise $625 million in a public offering.

Driven by these fast-growing market segments, the outlook for broad sector earnings growth is notably strong. Matthew Bartolini, global head of research strategists at State Street Investment Management, notes that analysts currently project the healthcare sector to post 21.9% year-over-year earnings growth in 2027, outpacing every other market sector except technology. Furthermore, these earnings projections have been subject to recent upward revisions. The biotech industry itself is expected to post an even more dramatic 47.7% surge in earnings by 2027, vastly outstripping the 15.1% growth projected for the broader S&P 500.

While a sudden spike in interest rates could theoretically pressure these earnings models, industry analysts suggest that robust macroeconomic fundamentals and continued upward revisions should counterbalance higher borrowing costs. Furthermore, many biotech firms restructured their balance sheets following the previous rate-hiking cycle, building cash reserves capable of supporting operations for multiple years rather than mere months.

How to invest in healthcare stocks

Healthcare Stocks Are on the Mend. Here Are 6 Ways Investors Can Cash In

Investors considering entering the biotech and healthcare space must remain mindful of the sector’s historical volatility, characterized by distinct boom-and-bust cycles that typically span four to five years. Because peaks and troughs can be extreme, portfolio sizing requires careful consideration, and long-term patience is essential. Drug development is notoriously lengthy and expensive—often taking more than a decade, though emerging artificial intelligence applications hold the potential to compress those timelines—with roughly 90% of therapies entering clinical development failing to reach the commercial market.

Investors seeking exposure to the biotech space can utilize a variety of specialized index-based exchange-traded funds and actively managed mutual funds. Passive options include the State Street SPDR S&P Biotech ETF, which tracks the S&P Biotechnology Select Industry Index and holds a diversified basket of small and midsize biotech firms where much of the foundational innovation and acquisition activity occurs. Similarly, the Virtus Biotech ETF tracks an index of equally weighted small and midsize firms that already have at least one FDA-approved drug therapy in their portfolio, providing a measure of stability during market downturns.

Active management also plays a critical role in the sector, as professional fund managers leverage specialized scientific expertise to navigate clinical trial outcomes and regulatory hurdles. Long-tenured managers overseeing dedicated portfolios like the Fidelity Select Biotechnology Portfolio, the T. Rowe Price Health ETF, the Eventide Healthcare & Life Sciences fund, and the Fidelity Select Health Care Portfolio continue to identify market leaders across small-cap, mid-cap, and large-cap segments.

As healthcare leaders continue to balance stable, earnings-generating pharmaceutical giants with innovative, clinical-stage disruptors, professionals across the industry remain cautiously optimistic about the durability of the sector’s ongoing recovery. While challenges remain, strengthening fundamentals and a robust pipeline of transformative medical breakthroughs point toward a bright horizon for healthcare investors.

No comments yet. Be the first to join the conversation!

Join the Discussion

Your email address will not be published. Required fields are marked *

Featured Articles